


CI-39

Cat. No.:	HY-146364
CAS No.:	2132412-25-8
Molecular Formula:	C ₁₉ H ₁₈ N ₂ O ₄
Molecular Weight:	338.36
Target:	HIV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	CI-39 is an antiviral natural product. CI-39 is an NNRTI (non-nucleoside reverse transcriptase inhibitor) antiviral agent with an EC ₅₀ of 3.40 μM and an CC ₅₀ of >30 μM for wild type HIV-1. CI-39 inhibits HIV-1 RT DNA polymerase and ribonuclease H activities ^[1] .	
IC₅₀ & Target	HIV-1 (WT) 3.40 μM (EC ₅₀)	HIV-1 (WT) >30 μM (CC ₅₀)
In Vitro	CI-39 (0-100 μM) inhibits HIV-1 RT DNA polymerase and ribonuclease H activities with EC ₅₀ s of 7.20, >30 μM, respectively ^[1] . CI-39 shows antiviral activities with EC ₅₀ s of 3.37, 3.00, 2.41, 3.08, 2.14, 3.27, 3.19, 4.07 μM for VSVG/HIV-1 _{WT} , VSVG/HIV-1 _{RT-K103N} , VSVG/HIV-1 _{WT} RT-K103N, VSVG/HIV-1 _{RT-K103N} , VSVG/HIV-1 _{RT-K103N,Y181C} , VSVG/HIV-1 _{RT-K103N,Y181C} , VSVG/HIV-1 _{RT-K103N,Y181C} , VSVG/HIV-1 _{RT-L100I,K103N} , VSVG/HIV-1 _{RT-Y188L} , VSVG/HIV-1 _{RT-K103N,G190A} , VSVG/HIV-1 _{RT-K103N,V108I} , respectively ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

REFERENCES

[1]. Xu C, et al. Discovery, synthesis, and optimization of an N-alkoxy indolylacetamide against HIV-1 carrying NNRTI-resistant mutations from the *Isatis indigotica* root. *Eur J Med Chem.* 2020 Mar 1;189:112071.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA